Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861966 | 1.00 | HCAR2 (0.41) | HCAR2KEAP1NFE2L2HPGDALDH1A1 | |
| SCHEMBL7109922 | 0.95 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2KMT2AMEN1 | |
| SCHEMBL16768108 | 0.95 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2KMT2AMEN1 | |
| SCHEMBL16768109 | 0.95 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2KMT2AMEN1 | |
| SCHEMBL31536661 | 0.81 | L3MBTL1 (0.47) | HCAR2HPGDALDH1A1NPC1RAB9A | |
| SCHEMBL18541691 | 0.79 | KMT2A (0.33) | KMT2AMEN1 | |
| SCHEMBL8948152 | 0.79 | KMT2A (0.33) | KMT2AMEN1 | |
| SCHEMBL34420051 | 0.79 | L3MBTL1 (0.34) | HPGDNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL31536634 | 0.78 | NPC1 (0.30) | ALDH1A1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17645629 | 0.77 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119081538-A | Post-crosslinking PMMA waterproof coating and preparation method thereof | 科顺防水科技股份有限公司 | 2024-12-06 | — | — | CN | claimed |
| US-9067930-B2 | 2-oxo-piperidinyl derivatives | UCB PHARMA, S.A. (BE) | 2015-06-30 | — | — | US | disclosed |
| EP-2766353-B1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2015-06-17 | — | — | EP | disclosed |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-01-08 | — | — | US | disclosed |
| EP-2766353-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013053725-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | CYP3A4, CYP2C19, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HCAR2 1014/4885KEAP1 2083/4885NFE2L2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.